Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Induction for Newly Diagnosed AML
NCT00274807Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Jun 2001
- Primary completion
- Apr 2007
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone, cytarabine and etoposide in acute myeloid leukemia (AML), sponsored by Cleveland Clinic. Primary endpoint: Complete Remission Rate. Started Jun 2001; status: completed.
02
Drugs
mitoxantronecytarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00274807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274807.